Abstract Library

#2939 Prognostic Evaluation for Gastroenteropancreatic NEC: AJCC or ENETS Staging Classification or Others?

Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Lin Z, Zhang T, Chen M,

Keywords: gastroenteropancreatic neuroendocrine carcinoma, prognosis, staging,

#2875 Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence

Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vandamme T, De Backer L, Van den Brande J, Op de Beeck B, Driessen A,

Keywords: NEC, immunotherapy,

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,

#2738 Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma

Introduction: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. Due to its low incidence and wide tissue distribution few representative preclinical models are available

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tesselaar M

Authors: Dijkstra K, van den Berg J, Weber F, van de Haar J, Velds A,

Keywords: organoids, gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), disease modeling, pre-clinical models,

#2257 Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study

Introduction: Neuroendocrine carcinomas (NEC) of the colon and rectum are aggressive and rare tumours. The Digestive Tract WHO classification 2010 defines the entity of large cell NEC (LCNEC) in contrast to small cell NEC (SCNEC).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Boeck I

Authors: Boeck I, Weihe E, Krieg A, Gabbert H, Raffel A,

Keywords: GEP-NEC, LCNEC, Colonic NEC,